Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 54Neoplasms 47Colorectal Neoplasms 31Prostatic Neoplasms 27Carcinoma, Non-Small-Cell Lung 24Lung Neoplasms 21Leukemia, Myeloid, Acute 19Recurrence 12Stomach Neoplasms 11Multiple Myeloma 11Melanoma 11Head and Neck Neoplasms 10Squamous Cell Carcinoma of Head and Neck 9Ovarian Neoplasms 9Uterine Cervical Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Pancreatic Neoplasms 8Neoplasm Metastasis 8Myelodysplastic Syndromes 8Lymphoma, Non-Hodgkin 8Lymphoma 8Glioma 8Brain Neoplasms 8Motor Activity 7Esophageal Neoplasms 7Carcinoma, Renal Cell 7Carcinoma, Hepatocellular 7Leukemia 6Hodgkin Disease 6Colonic Neoplasms 6

Interventions

zanidatamab 1tislelizumab 1sitravatinib 1pamiparib 1lenvatinib 1Temozolomide 1HMPL-013 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Malignancies × 30 days × Clear all
NCT04164199 2026-06-03

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

BeOne Medicines

Phase 3 Completed
404 enrolled

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡